E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
Type 1 diabetes is a metabolic disease characterised by deficient insulin production |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Hormonal diseases [C19] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10067584 |
E.1.2 | Term | Type 1 diabetes mellitus |
E.1.2 | System Organ Class | 10027433 - Metabolism and nutrition disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To compare the effect of low-dose glucagon (single 150 µg dose) administered immediately before aerobic exercise (visit B) versus a control trial without glucagon (visit C) on glucose responses during and after exercise in individuals with AHCL-treated T1D. |
|
E.2.2 | Secondary objectives of the trial |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Age ≥ 18 years • Type 1 diabetes ≥ 2 years • Using the AHCL system MiniMed 780G ≥ 4 weeks • Novorapid use ≥1 week
|
|
E.4 | Principal exclusion criteria |
• Allergies to lactose or glucagon • Known or suspected allergies to glucagon or related products • History of hypersensitivity or allergic reaction to glucagon or lactose • Patients with diagnosed pheochromocytoma, insulinoma or gastroparesis • Concomitant medical or psychological conditions identified through review of medical history, physical examination and clinical laboratory analysis that, according to the investigator's assessment, makes the individual unsuitable for study participation • Lack of compliance with key study procedures at the discretion of the investigator • Females of childbearing potential who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods (methods are considered adequate for study enrolment for females: an intrauterine device, hormonal contraception (birth control pills, implant, patch, vaginal ring or injection), a single partner who is sterile or infertile, or sexual abstinence. Contraception is required throughout the study duration. Sterilized or postmenopausal women (>12 months since last period) are not required to use contraception) • Inability to understand the individual information and to give informed consent
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Difference in percentage of time in target glucose range (PG: 3.9 - 10.0 mmol/l) during and for 1-hour after dynamic physical exercise (0 min to +105min) between visits B and C.
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
From 105 min post-intervention |
|
E.5.2 | Secondary end point(s) |
The Difference between visit B and C will be compared for the following: • Incidence rate of hypoglycaemic events (PG<3.9 mmol/l) (0 min to +105min) • Time (min) to hypoglycaemia (PG<3.9 mmol/l) (0 min to +105min) • Percentage of time below target glucose range (PG<3.9 mmol/l) (0 min to +105min) • Percentage of time above target glucose range (PG>10.0 mmol/l) (0 min to +105min) • Incidence rate of hyperglycaemia (PG>10.0 mmol/l) (0 min to +105min) • Nadir PG concentration (0 min to +105min) • Peak PG concentration (0 min to +105min) • Incremental peak PG concentration (0 min to +105min) • Mean PG concentration (0 min to +105min) • PG Area Under the Curve (AUC) (0 min to +105min) • Standard deviation in PG concentrations (0 min to +105min) • Coefficient of variation in PG concentrations (0 min to +105min)
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
From 105 min post-intervention |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | Yes |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
A two period, crossover interventional study, in which there will be no randomization or blinding |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
The comparator is a visit without injection of glucagon before exercise |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | |